Trial Profile
Targeting Complete Response in Younger transplant-eligible Multiple myeloma patients with Bortezomib and Lenalidomide treatment after relapse with autologous stem cell transplantation
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 20 Mar 2020
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Bortezomib (Primary) ; Lenalidomide (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms CYMBAL
- 01 Jul 2014 New trial record